Company news

EMV Capital PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PDS Announces Presentation at ASCO Annual Meeting

April 30, 2021

EMV Capital Advises on £740k Fundraise for Sofant

April 28, 2021

Preliminary Results for the year ended 31 Dec 2020

March 31, 2021

PDS Reports Results for FY2020 & Business Update

March 18, 2021

$60m Commitment for PDS Vaccine Consortium

March 11, 2021

PDS Biotech Consortium Update

February 23, 2021

PDS Phase II Trial Update & Restoration of Trading

February 3, 2021

Suspension of Trading on AIM

February 2, 2021

Issue of Shares, Director/PDMR Shareholding & TVR

January 25, 2021

PDS Announces Publication of Data by Mount Sinai

December 21, 2020

ProAxsis awarded Innovate UK grant

December 10, 2020

Board changes and Grant of Options

December 2, 2020

EMV Capital leads a £1.28m investment in SageTech

November 30, 2020

ProAxsis appoints DiaPharma as distributor

November 19, 2020

PDS updates on Versamune based COVID-19 vaccine

November 11, 2020

PDS Biotech Initiates VERSATILE-002 Phase 2 Trial

November 10, 2020

PDS Announces Initiation of PDS0101 Phase 2 Trial

October 27, 2020

NetScientific acquires 100% of portfolio company

October 16, 2020

Grant of Options to Director

September 25, 2020

Result of General Meeting

August 24, 2020

PDS Announces Closing of $19m Offering

August 14, 2020

Sofant secures £2.3m funding led by EMV Capital

August 12, 2020

PDS Announces Proposed Offering of Common Stock

August 11, 2020

Posting of shareholder circular

August 7, 2020

Result of Placing

August 5, 2020

PDS Announces Preclinical Data for PDS0203

July 27, 2020

PDS collaborator awarded grant for Versamune

July 14, 2020

G-Tech Medical completes $6.7m Series A financing

June 29, 2020

PDS & Farmacore Announce Co-Development-PDS0204

June 18, 2020

PDS Announces Initiation of Phase 2 Trial PDS0101

June 15, 2020

PDS Announces Trial of its Lead Product, PDS0101

June 5, 2020

PDS Reports Results for Q1 2020 & Business Update

May 13, 2020

Confirmation of Board Changes

May 1, 2020

PDS expands CRADA with National Cancer Institute

April 30, 2020

Preliminary Results for the year ended 31 Dec 2019

April 27, 2020

PDS Initiates Programs for COVID-19, PDS0101 delay

April 16, 2020

PDS Appoints Ilian Iliev to the Board

April 14, 2020

PDS equity issue and related party transaction

February 12, 2020

PDS Biotechnology proposed offering

February 11, 2020

Glycotest receives 2nd $3m tranche of $10m finance

November 21, 2019

Appointment to the Board

October 14, 2019

PDS collaborates with Merck in Phase 2 studies

October 3, 2019

PDS prioritise PDS0101 in high risk HPV to Phase 2

October 1, 2019

PDS - positive data for immunotherapy treatment

September 19, 2019

PDS second quarter 2019 financial results

August 1, 2019

PDS Biotechnology Corp liquidity funding program

July 31, 2019

Result of Annual General Meeting

June 18, 2019

Positive new data demonstrates NEATstiks potential

May 31, 2019

Full Year Results for the year ended 31 Dec 2018

May 22, 2019

PDS Biotechnology journal publication

May 16, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.